SanaCurrents assigns an advantageous probability PDS Biotechnology and its partner, the MD Anderson Cancer Center, will report positive data later this year from their cervical cancer trial, which combines PDS0101 and chemoradiation therapy.
SanaCurrents assigns an advantageous probability PDS Biotechnology and its partner, the MD Anderson Cancer Center, will report positive data later this year from their cervical cancer trial, which combines PDS0101 and chemoradiation therapy.